"Herpes Zoster Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.
| Descriptor ID |
D053061
|
| MeSH Number(s) |
D20.215.894.899.290.130.400
|
| Concept/Terms |
Herpes Zoster Vaccine- Herpes Zoster Vaccine
- Vaccine, Herpes Zoster
- Zoster Vaccine
- Vaccine, Zoster
- Shingles Vaccine
- Vaccine, Shingles
|
Below are MeSH descriptors whose meaning is more general than "Herpes Zoster Vaccine".
Below are MeSH descriptors whose meaning is more specific than "Herpes Zoster Vaccine".
This graph shows the total number of publications written about "Herpes Zoster Vaccine" by people in this website by year, and whether "Herpes Zoster Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Herpes Zoster Vaccine" by people in Profiles.
-
Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged =50 years in the United States. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2327145.
-
Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. BMJ. 2023 Nov 08; 383:e076321.
-
Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine. Vaccine. 2023 Jul 05; 41(30):4392-4401.
-
Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data. Am J Epidemiol. 2023 Feb 01; 192(2):205-216.
-
Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):643-649.
-
In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barré syndrome. Ann Intern Med. 2022 03; 175(3):JC35.
-
Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021 02 05; 39(6):926-932.
-
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J Manag Care Spec Pharm. 2020 Dec; 26(12):1567-1575.
-
Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019 08 23; 37(36):5422-5427.
-
Evaluation of two frailty indices, with practical application in a vaccine clinical trial. Hum Vaccin Immunother. 2019; 15(12):2960-2968.